PDCD1 and neoplasm: Anti-PD-1 and anti-TIGIT dual immune checkpoint treatment in murine intracranial tumors has synergistic effects in enhancing antitumor functions of effector T cells and decreasing suppressive tumor-infiltrating DCs and Tregs, thereby conferring significant survival benefit [111].